Request Demo
Last update 05 Nov 2026
Beijing Silian Pharmaceutical Co., Ltd.
Last update 05 Nov 2026
Overview
Tags
Digestive System Disorders
Congenital Disorders
Endocrinology and Metabolic Disease
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20262706
生物素片在中国健康试验参与者中随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的空腹和餐后状态下生物等效性试验。
[Translation] A randomized, open-label, single-dose, two-formulation, two-cycle, two-sequence, self-crossover bioequivalence study of biotin tablets in healthy participants in China, under fasting and postprandial conditions.
CTR20260226
一项随机、开放、四周期、完全重复交叉、餐后状态下给药临床试验，评价瑞舒伐他汀依折麦布片(I)与旨立达在中国健康成年参与者中的生物等效性
[Translation] A randomized, open-label, four-period, fully repeated crossover, postprandial administration clinical trial was conducted to evaluate the bioequivalence of rosuvastatin ezetimibe tablets (I) and zebufenib in healthy adult participants in China.
CTR20262148
生物素片在中国健康试验参与者中随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的空腹和餐后状态下生物等效性预试验
[Translation] A preliminary bioequivalence study of biotin tablets in Chinese healthy participants under randomized, open-label, single-dose, two-formulation, two-period, two-sequence, self-crossover fasting and postprandial conditions.
100 Clinical Results associated with Beijing Silian Pharmaceutical Co., Ltd.
Login to view more data
Login to view more data
01 Jan 2026JPAD-Journal of Prevention of Alzheimers Disease
Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial
Article
Author: Yu, Zili ; Guo, Yajie ; Wang, Yanhong ; Wang, Yu ; Miao, Yuli ; Su, Xiaonan ; Yi, Bin ; Liu, Yinyue ; Zhao, Li ; Zhang, Xumei ; Cai, Zhengjun
BACKGROUND:
The potential improvement of cognitive function through folic acid (FA) supplementation in patients with vascular cognitive impairment (VCI) remains unclear, and no randomized controlled trials (RCTs) have been conducted specifically in populations with cerebral small vessel disease-related cognitive impairment (CSVD-CI).
OBJECTIVE:
This study aimed to explore the effects of FA supplementation on cognitive function and angiogenesis-related indicators in patients with CSVD-CI.
DESIGN:
Double-blinded, parallel group, randomized controlled trial, with a six-month follow-up period.
SETTING:
Department of neurology and neurosurgery in Shanxi, China.
PARTICIPANTS:
220 CSVD-CI patients.
INTERVENTIONS:
The intervention consisted of FA tablets (0.4 mg/tablet) administered orally at a dose of two tablets daily for six months, while the placebo tablets were identical in appearance and administration but lacked FA.
MEASUREMENTS:
The primary outcome was the Montreal Cognitive Assessment (MoCA) score at six months assessed in the intention-to-treat (ITT) population. Secondary outcomes included Mini-Mental State Examination (MMSE) score, Trail Making Test (TMT), Tinetti Performance Oriented Mobility Assessment (POMA), and five-level EuroQol five-dimensional questionnaire (EQ-5D-5 L).
RESULTS:
MoCA and MMSE scores improved significantly in the FA group compared to placebo (both P < 0.05). Additionally, the FA group had statistically significant increases in serum folate and decreases in serum homocysteine (Hcy) (both P < 0.001). Matrix metalloproteinase-9 (MMP-9) expression decreased significantly in the FA group compared with placebo (P < 0.05).
CONCLUSIONS:
FA improved cognitive outcomes in CSVD-CI, accompanied by a reduction in serum Hcy levels and MMP-9 expression. Early FA supplementation could help prevent vascular-related cognitive decline in CSVD-CI patients.
100 Deals associated with Beijing Silian Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Beijing Silian Pharmaceutical Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 07 Nov 2026
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
3
1
Phase 2
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free